KYMR vs. ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, and LNTH
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Kymera Therapeutics vs.
Roivant Sciences (NASDAQ:ROIV) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
In the previous week, Roivant Sciences had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 12 mentions for Kymera Therapeutics. Roivant Sciences' average media sentiment score of 1.40 beat Kymera Therapeutics' score of 1.24 indicating that Roivant Sciences is being referred to more favorably in the media.
Roivant Sciences has a net margin of -119.54% compared to Kymera Therapeutics' net margin of -191.26%. Roivant Sciences' return on equity of -14.05% beat Kymera Therapeutics' return on equity.
Roivant Sciences has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
Roivant Sciences presently has a consensus price target of $17.50, suggesting a potential upside of 59.96%. Kymera Therapeutics has a consensus price target of $55.25, suggesting a potential upside of 83.13%. Given Kymera Therapeutics' higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Roivant Sciences.
Kymera Therapeutics received 5 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 54.55% of users gave Kymera Therapeutics an outperform vote.
64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Roivant Sciences has higher revenue and earnings than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Roivant Sciences beats Kymera Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYMR) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy KYMR Stock Free KYMR Stock Alerts